SELEGILINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Selegiline Hydrochloride patents expire, and what generic alternatives are available?
Selegiline Hydrochloride is a drug marketed by Apotex, Lannett Co Inc, Novitium Pharma, Rising, Apotex Inc, Chartwell Molecules, Cosette, Dash Pharms Natco, G And W Labs Inc, I3 Pharms, Kenton, and Norvium Bioscience. and is included in fourteen NDAs.
The generic ingredient in SELEGILINE HYDROCHLORIDE is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Selegiline Hydrochloride
A generic version of SELEGILINE HYDROCHLORIDE was approved as selegiline hydrochloride by I3 PHARMS on April 1st, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SELEGILINE HYDROCHLORIDE?
- What are the global sales for SELEGILINE HYDROCHLORIDE?
- What is Average Wholesale Price for SELEGILINE HYDROCHLORIDE?
Summary for SELEGILINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 10 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 38 |
Patent Applications: | 668 |
DailyMed Link: | SELEGILINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for SELEGILINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Ibadan | Phase 1/Phase 2 |
E-Group ICT Software Informatikai Zrt. | Phase 2 |
László Mangel | Phase 2 |
Pharmacology for SELEGILINE HYDROCHLORIDE
Drug Class | Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor |
Mechanism of Action | Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors |